PAR1 COST-EFFECTIVENESS ANALYSIS OF ETANERCEPT VS INFLIXIMAB FOR TREATMENT OF SEVERE RHEUMATOID ARTHRITIS IN BRAZIL
Nov 1, 2006, 00:00 AM
10.1016/S1098-3015(10)63260-3
https://www.valueinhealthjournal.com/article/S1098-3015(10)63260-3/fulltext
Section Title :
Section Order :
111
First Page :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(10)63260-3&doi=10.1016/S1098-3015(10)63260-3